IMmotion-150 (At - all population), 2018 NCT01984242
atezolizumab alone (n=103) vs. sunitinib (n=101)
randomized controlled trial
atezolizumab
atezolizumab 1,200mg fixed intravenous dose every three weeks
sunitinib
sunitinib 50mg/d orally for four weeks followed by two weeks of rest
3 bras : atezolizumab, atezolizumab and bevacizumab, sunitinib, patients randomized to atezolizumab monotherapy or sunitinib had the option to cross over and receive the atezolizumab bevacizumab combination in some regions
metastatic/advanced RCC (mRCC) - 1st line (L1)
patients had a Karnofsky performance score ≥ 70, . Patients were required to have adequate hematologic and end-organ function.
open-label
96 institution
P2/interim analysis planned but no treshhold, no stratistic plan found (no protocol)
Overall, data from IMmotion150 suggest (did not demonstrare PFS benefit) that atezolizumab plus bevacizumab may particularly enhance PFS benefit in patients with pre-existing antitumor immunity (as determined by a high Teff score and PD-L1 IC expression) compared with sunitinib
IMmotion-150 (At - PDL1>1%), 2018 NCT01984242
atezolizumab alone (n=54) vs. sunitinib (n=60)
randomized controlled trial
atezolizumab
atezolizumab 1,200mg fixed intravenous dose every three weeks
sunitinib
sunitinib 50mg/d orally for four weeks followed by two weeks of rest
3 bras : atezolizumab, atezolizumab and bevacizumab, sunitinibpatients randomized to atezolizumab monotherapy or sunitinib had the option to cross over and receive the atezolizumab bevacizumab combination in some regions
mRCC - L1 - PDL1 positive
patietns had a Karnofsky performance score ≥ 70, . Patients were required to have adequate hematologic and end-organ function.
open-label
96 institution
P2/interim analysis planned but no treshhold, no stratistic plan found (no protocol)
Overall, data from IMmotion150 suggest (did not demonstrare PFS benefit) that atezolizumab plus bevacizumab may particularly enhance PFS benefit in patients with pre-existing antitumor immunity (as determined by a high Teff score and PD-L1 IC expression) compared with sunitinib